Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
نویسندگان
چکیده
and these results were considered the reference standard against which all other results were compared. Temocillin Etests were used according to the manufacturer's instructions. Susceptibility to temocillin using the Phoenix system was determined according to BSAC breakpoints for Enterobacteriaceae for systemic infections (susceptible if MIC ≤8 mg/L). 3 If the Etest or Phoenix results were within a 2-fold dilution of the BMD MIC for an isolate, the methods were deemed as being in agreement. Unless the Phoenix result advised a retest, e.g. due to insufficient growth, the first test results were used for the evaluation and comparison of the different antimicrobial susceptibility testing (AST) methods. Disagreements between BMD and the Etest or Phoenix methods were then subjected to further investigation by repeating the Phoenix test in duplicate. Etest MICs showed good correlation with those obtained by BMD—they were within one doubling dilution in 93.6% of isolates. Overall, there appeared to be discrepant results between the Phoenix system and one of the alternative susceptibility methods for 102 isolates (97 deemed intermediate by Phoenix and 5 deemed resistant) and a discrepancy between Phoenix and both other methods in 93. Therefore, Phoenix AST was repeated, in duplicate, for the 102 isolates to confirm or refute the original Phoenix result. Of these 102 isolates, the second and third Phoenix AST results were consistent with the original result for 88 (86.3%). However, for 17 (16.7%) samples, the initial Phoenix AST result was not consistent between runs—these results were therefore excluded from our analysis. Of the 264 remaining isolates, 246 were proven to be susceptible using BMD (MIC ≤8 mg/L) and concordant results were found by Etest in 236 (95.9%). However, the Phoenix system declared only 162 (65.9%) susceptible. Seventeen isolates were 'susceptible only for UTI' (MIC .8 to ≤32 mg/L) by BMD and 26 by Etest. In comparison, far more were categorized as 'susceptible only for UTI' by Phoenix—96. Only one isolate was found to be resistant (MIC .32 mg/L) by the reference method, and two by Etest, whereas six were declared resistant by the Phoenix method. Table 1 summarizes the results for temocillin susceptibility for all three methods. In conclusion, this study indicates that 'susceptible' results produced by the Phoenix system, using the NMIC-84 card according to the manufacturer's recommendations, are reliable. However, the majority of isolates found to be 'susceptible only for UTI' and 'resistant' by Phoenix were actually fully susceptible (MIC ≤8 …
منابع مشابه
Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child.
report of maraviroc plasma concentrations when the drug is given as 150 mg once daily with lopinavir/ ritonavir. It is noteworthy that the current recommended minimum effective values of the trough concentration (50 ng/mL) and average concentration (100 ng/mL) were derived from a sub-study of the MOTIVATE trial, 3 where patients were administered 150 mg of maraviroc once daily or twice daily: t...
متن کاملSeminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.
Sir, Sexual transmission of HIV-1 is currently the major way of viral spread worldwide: the quantification of seminal HIV-1 RNA has been clearly linked to the risk of transmission. The use of highly active antiretroviral treatment, besides providing immunovirological benefits, has been associated with viral control in the genital compartment of males and females. Nevertheless, occasional HIV-1 ...
متن کاملOnce daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
OBJECTIVES To describe the pharmacokinetics of maraviroc when dosed at 150 or 300 mg once daily with 800/100 mg of darunavir/ritonavir. METHODS A retrospective case-note review of HIV-infected adults taking maraviroc was conducted. Patients on a maraviroc-based regimen for a minimum of 5 weeks were grouped as receiving: (i) 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of em...
متن کاملLopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
OBJECTIVES Lopinavir/ritonavir is approved for treatment of HIV-infected children at a dosage regimen of 230/57.5 mg/m(2) twice daily. However, once daily administration could increase convenience and patient adherence. Our study aimed at evaluating whether inhibitory concentrations are maintained in plasma following administration of lopinavir/ritonavir once daily. PATIENTS AND METHODS Lopin...
متن کاملPopulation pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
OBJECTIVES Darunavir is a protease inhibitor that is administered with low-dose ritonavir to enhance its bioavailability. It is prescribed at standard dosage regimens of 600/100 mg twice daily in treatment-experienced patients and 800/100 mg once daily in naive patients. A population pharmacokinetic approach was used to characterize the pharmacokinetics of both drugs and their interaction in a ...
متن کاملHIV Treatment Bulletin (HTB) September/October 2009
s from the workshop, published in Reviews in Antiviral Therapy & Infectious Diseases 2011_3 are available to download from the meeting website. http://www.virology-education.com/index.cfm/t/Workshop_Materials/vid/34792068-01CF-4196-986A8271C014BBD7 Selected presentations are also available online. http://regist2.virology-education.com/2011/12HIV_PK/13_April.html Articles included in this issue ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of antimicrobial chemotherapy
دوره 68 7 شماره
صفحات -
تاریخ انتشار 2013